In:
Cardiology, S. Karger AG, Vol. 117, No. 2 ( 2010), p. 131-139
Abstract:
〈 i 〉 Objectives: 〈 /i 〉 This study tested the hypothesis that the level of apoptotic and necrotic peripheral blood mononuclear cells (PBMCs) is a predictor of the 30-day combined major adverse clinical outcome (MACO) [defined as advanced congestive heart failure (CHF), a high Killip score, or 30-day mortality] in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). 〈 i 〉 Methods: 〈 /i 〉 Between April 2009 and January 2010, 98 patients undergoing primary PCI were assessed for both apoptotic and necrotic PBMCs (apoptotic cells are referred to as annexin V+/propidium iodide– and necrotic cells are defined as annexin V+/propidium iodide+) using flow cytometry 24 h after STEMI. Patients with higher (≧3.2%) and lower ( 〈 3.2%) levels of necrotic cells were categorized into group 1 (n = 40) and group 2 (n = 58), respectively, according to the ROC curve method. 〈 i 〉 Results: 〈 /i 〉 Higher incidences of advanced CHF and a high Killip score were noted in group 1 patients (p 〈 0.0001). Moreover, the peak level of creatine phosphokinase was higher in group 1 (p 〈 0.0001), whereas the left ventricular ejection fraction was lower in group 1 than in group 2 (p 〈 0.001). Multivariate analysis revealed that high necrotic cells (≧3.2%) was the strongest independent predictor of 30-day MACO (p = 0.001). 〈 i 〉 Conclusion: 〈 /i 〉 A high level of necrotic cells (PBMCs) may serve as a useful biomarker for predicting 30-day MACO in patients with STEMI undergoing primary PCI.
Type of Medium:
Online Resource
ISSN:
0008-6312
,
1421-9751
Language:
English
Publisher:
S. Karger AG
Publication Date:
2010
detail.hit.zdb_id:
1482041-9
Permalink